Stockscreener 앱 받기
5.63
0.18%
0.010
Tenax Therapeutics Inc 주식(TENX)의 최신 뉴스
Geode Capital Management LLC Boosts Stock Position in Tenax Therapeutics, Inc. (NASDAQ:TENX) - Defense World
Tenax Therapeutics (NASDAQ:TENX) Coverage Initiated at StockNews.com - Defense World
Form SC 13G/AStatement of Beneficial Ownership by Certain Investors: [Amend] - ADVFN
SEC Form DEF 14A filed by Tenax Therapeutics Inc. - Quantisnow
Form DEF 14A TENAX THERAPEUTICS, INC. For: Apr 24 - StreetInsider
Tenax Therapeutics Advances Cardiopulmonary Therapies - TipRanks
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - The Globe and Mail
Tenax Therapeutics (NASDAQ:TENX) Coverage Initiated by Analysts at StockNews.com - Defense World
Oxygen Biotherapeutics, Inc. : Oxygen Biotherapeutics Announces Third Quarter FY2013 Financial Results Conference Call and Webcast - marketscreener.com
Teanx Therapeutics plans secondary offering - MSN
Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts - Seeking Alpha
Tenax Therapeutics (TENX) Files Prospectus for Stock Resale - GuruFocus
Tenax Therapeutics (NASDAQ:TENX) Now Covered by StockNews.com - Defense World
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Exclusive: Tenax Leadership Team to Unveil Latest Phase 3 Progress at Major Healthcare Conference - Stock Titan
What is Leerink Partnrs’ Forecast for TENX Q1 Earnings? - Defense World
Equities Analysts Offer Predictions for TENX Q1 Earnings - Defense World
Q1 Earnings Estimate for TENX Issued By William Blair - Defense World
Tenax Therapeutics (NASDAQ:TENX) Earns Sell Rating from Analysts at StockNews.com - Defense World
Research Analysts Set Expectations for TENX Q1 Earnings - Defense World
When (TENX) Moves Investors should Listen - news.stocktradersdaily.com
Tenax Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Tenax Therapeutics: Q4 Earnings Snapshot - CT Insider
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - Bluefield Daily Telegraph
Tenax Raises Massive $125M War Chest: Phase 3 Heart Failure Drug Trial Gets Major Boost - Stock Titan
Tenax Therapeutics Inc expected to post a loss of 42 cents a shareEarnings Preview - TradingView
Tenax Therapeutics (NASDAQ:TENX) Now Covered by Analysts at StockNews.com - Defense World
Tenax Therapeutics (TENX) to Release Earnings on Thursday - Defense World
Plastic Fencing Market to be Driven by Growing Residential and Commercial Construction Activities, Exclusive Research by The Insight Partners - GlobeNewswire Inc.
Tenax Therapeutics (NASDAQ:TENX) Given “Outperform” Rating at William Blair - Defense World
Promising Developments and Financial Backing Drive Buy Rating for Tenax Therapeutics - TipRanks
What is Roth Capital’s Estimate for TENX FY2024 Earnings? - Defense World
Roth Capital Predicts Weaker Earnings for Tenax Therapeutics - Defense World
(TENX) Proactive Strategies - news.stocktradersdaily.com
Tenax Therapeutics Announces $25 Million Private Placement - GlobeNewswire
Tenax Therapeutics announces $25M private placement - MSN
Tenax Therapeutics prices 378,346 shares at $6.04 in private placement - TipRanks
Tenax Therapeutics expands Phase 3 LEVEL program for TNX-103 - TipRanks
Tenax Therapeutics secures $25 million in private placement - Investing.com India
Tenax Therapeutics Announces $25 Million Private Placement -March 05, 2025 at 08:54 am EST - Marketscreener.com
Tenax Therapeutics secures $25 million in private placement By Investing.com - Investing.com UK
Tenax Therapeutics Secures $25 Million From RTW Investments For Phase 3 Clinical Trials - StockTitan
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing - GlobeNewswire
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF - Yahoo Finance
Bristol Myers’ MyoKardia unit ends work with Fulcrum; ALX discloses layoffs - Endpoints News
1.72%
0.85%
자본화:
|
볼륨(24시간):